 |
|
|
|
|
|
|
|
Management Team
 |
|
Masahisa Kitagawa
President and CEO
|
Masahisa Kitagawa has served as the president of Teikoku Pharma USA (TPU) since co-founding the company in June 1997. Mr. Kitagawa has worked for Teikoku Pharma's parent company in Japan—Teikoku Seiyaku Company Limited (TSC)—and its subsidiaries for 23 years. At TSC, he held progressively more responsible managerial positions, the most recent as senior director of the International Division. Under his leadership, TSC and TPU acquired successful products for the Japanese market, such as Leo Pharmaceutical's Dovonex ointment. Mr. Kitagawa remains TSC's managing director for research and development and a member of TSC's board of directors. He received his bachelor's degree from the Science University of Tokyo and began his career at Daiwa Chemical.
|
|
|
|
|
|
 |
Copyright © 2006 Teikoku Pharma USA, Inc. All Rights Reserved.
Teikoku Pharma USA, Teikoku, Teikoku Pharma, Teikoku Seiyaku Co., drug delivery systems, TDS, patches, unit-dose jellies, unit-dose liquids, creams and ointments, delivery products, pain management, cosmetic care, TDS technologies, patent protections, prescription, otcs, medical device market, applications, transdermal drug delivery technologies, Lidoderm, Endo Pharmaceuticals, post-herpetic neuralgia, TDS-based health and beauty products, face masks, anti-wrinkle patches, skin whiteners, and cuticle softe
|
|
